Carregant...
Efficacy and safety of a GABAergic drug (Gamalate® B6): effects on behavior and cognition in young adults with borderline-to-mild intellectual developmental disabilities and ADHD
BACKGROUND: We evaluated Gamalate® B6 (GB6) in patients with borderline intellectual functioning (BIF) or mild intellectual development disability (IDD). PATIENTS AND METHODS: This was a prospective phase IV observational pilot study in 30 patients who underwent neuropsychological evaluation during...
Guardat en:
| Publicat a: | Drugs Context |
|---|---|
| Autors principals: | , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
BioExcel Publishing Ltd
2020
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7048157/ https://ncbi.nlm.nih.gov/pubmed/32158489 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7573/dic.212601 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|